Literature DB >> 22583139

Rituximab and thalidomide combination therapy for Castleman disease.

Karthik Ramasamy, Shreyans Gandhi, Melinda Tenant-Flowers, Mansour Ceesay, Sophie Corderoy, Robert Marcus, Stephen Schey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22583139     DOI： 10.1111/j.1365-2141.2012.09157.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

2.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

3.  Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.

Authors:  Shotaro Tatekawa; Koji Umemura; Ryuichi Fukuyama; Akio Kohno; Masafumi Taniwaki; Junya Kuroda; Yoshihisa Morishita
Journal:  Clin Case Rep       Date:  2015-04-22

4.  Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.

Authors:  Q Lin; B Fang; H Huang; F Yu; X Chai; Y Zhang; J Zhou; Q Xia; Y Li; Y Song
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037

Review 5.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

6.  TAFRO Syndrome - A Specific Subtype of Castleman's Disease in China.

Authors:  Wan-Lu Ma; Lu Zhang; Tie-Nan Zhu; Dao-Bin Zhou; Jian Li; Jian Sun; Bo-Ju Pan; Wei-Xing Xu
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

7.  Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.

Authors:  Yi Zhang; Shan-Shan Suo; Han-Jin Yang; Xin-Ping Zhou; Liang-Shun You; Wen-Juan Yu; Zhao-Ming Wang; Jie Jin
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-14       Impact factor: 4.553

8.  The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.

Authors:  David C Fajgenbaum; Sheila K Pierson; Karan Kanhai; Adam Bagg; Daisy Alapat; Megan S Lim; Mary Jo Lechowicz; Gordan Srkalovic; Thomas S Uldrick; Frits van Rhee
Journal:  Br J Haematol       Date:  2022-05-04       Impact factor: 8.615

9.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.